Варианты локального лечения олигометастатического поражения печени при колоректальном раке: обзор литературы

Варианты локального лечения олигометастатического поражения печени при колоректальном раке: обзор литературы

Автор: Москаленко А. Н., Лядов В. К., Сагайдак И. В., Черных М. В., Брицкая Н. Н.

Журнал: Злокачественные опухоли @malignanttumors

Рубрика: Обзор и аналитика

Статья в выпуске: 4 т.11, 2021 года.

Бесплатный доступ

Метастазирование в печень является наиболее частым вариантом прогрессирования рака толстой кишки. Наивысшие показатели выживаемости отмечаются у пациентов, которые успешно переносят хирургическое удаление метастазов и системную противоопухолевую терапию. Выделение олигометастатической болезни как отдельного феномена позволило дифференцировать в группе больных диссеминированным раком пациентов, у которых применение локальных методов воздействия на метастазы наиболее оправдано. В современном арсенале клинического онколога имеется несколько инструментов локального деструктивного воздействия на метастатические очаги в печень: резекция, стереотаксическая лучевая терапия, радиочастотная или микроволновая абляция, необратимая электропорация, криодеструкция. Целью нашего обзора является сравнительная оценка эффективности вышеперечисленных методик, их преимуществ и недостатков

Еще

Олигометастазы, резекция печени, колоректальный рак, стереотаксическая лучевая терапия

Короткий адрес: https://sciup.org/140290752

IDR: 140290752   |   DOI: 10.18027/2224-5057-2021-11-4-29-38

Список литературы Варианты локального лечения олигометастатического поражения печени при колоректальном раке: обзор литературы

  • F. Bray, J. Ferlay, I. Soerjomataram et al. "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries," CA. Cancer J. Clin., vol. 68, no. 6, pp. 394-424, Nov. 2018.
  • Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой Злокачественные новообразования в России в 2017 году (заболеваемость и смертность) М.: МНИОИ им. П. А. Герцена филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. илл. 250 с. ISBN 978-5-85502-243-8.
  • Van Cutsem E, Nordlinger B, Adam R, Kohne CH, Pozzo C, Poston G, et al. European Colorectal Metastases Treatment Group. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006 Sep;42 (14):2212-21. doi: 10.1016/j. ejca. 2006.04.012. Epub 2006 Aug 10. PMID: 16904315.
  • Adam R, De Gramont A, Figueras J et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. The Oncologist 2012; 17:1225-1239.
  • Adam R, De Gramont A, Figueras J et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treatment Reviews 2015; 41:729-741.
  • Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13: 8-10.
  • Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget. 2015;6 (11):8491-8524. doi:10.18632/ oncotarget. 3455.
  • Guckenberger M., Lievens Y., Bouma AB., Collette L., Dekker A., deSouza NM, Dingemans AMC et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 2020 Jan;21 (1):e18-e28. doi: 10.1016/S1470-2045 (19) 30718-1.
  • Ashworth AB, Senan S, Palma DA, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer 2014;15:346e55.
  • Yoo GS, Yu JI, Park W, Huh SJ, Choi DH. Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy. Radiat Oncol J 2015;33:301e9.
  • Conde Moreno AJ, Ferrer Albiach C, Muelas Soria R, Gonzalez Vidal V, Garcia Gomez R, Albert Antequera M. Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options. Radiat Oncol (London, England) 2014;9:258.
  • Ciliberto D, Prati U, Roveda L, Barbieri V, Staropoli N, Abbruzzese A, Caraglia M, Di Maio M, Flotta D, Tassone P, Tagliaferri P. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. Oncol Rep. 2012 Jun;27 (6):1849-56. doi: 10.3892/ or. 2012.1740. Epub 2012 Mar 22. PMID: 22446591.
  • Araujo R, Gonen M, Allen P, Blumgart L, DeMatteo R, Fong Y, Kemeny N, Jarnagin W, D'Angelica M. Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer. Ann Surg Oncol. 2013 Dec;20 (13):4312-21. doi: 10.1245/s10434-013-3162-8. Epub 2013 Jul 30. PMID: 23897009.
  • Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. 2006 May;141 (5):460-6; discussion 466-7. doi: 10.1001/archsurg. 141.5.460. PMID: 16702517.
  • Hur H, Ko YT, Min BS, Kim KS, Choi JS, Sohn SK, Cho CH, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg. 2009 Jun;197 (6):728-36. doi: 10.1016/j. amjsurg. 2008.04.013. Epub 2008 Sep 11. PMID: 18789428.
  • Lee WS, Yun SH, Chun HK, Lee WY, Kim SJ, Choi SH, et al. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. J Clin Gastroenterol. 2008 Sep;42 (8):945-9. doi: 10.1097/ MCG. 0b013e318064e752. PMID: 18438208.
  • Figueras J, Torras J, Valls C, Llado L, Ramos E, Marti-Rague J, et al. Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum. 2007;50 (4):478-88.
  • Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247 (1):125-35.
  • Pulitano C, Bodingbauer M, Aldrighetti L, de Jong MC, Castillo F, Schulick RD, et al. Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol. 2011 May;18 (5):1380-8. doi: 10.1245/s10434-010-1459-4. Epub 2010 Dec 7. PMID: 21136180.
  • Sawada Y., Sahara K,. Endo I., Sakamoto K., Honda G., Beppu T., Kotake K et al. Long-term outcome of liver resection for colorectal metastases in the presence of extrahepatic disease: A multi-institutional Japanese study. J Hepatobiliary Pancreat Sci 2020;27 (11):810-818. doi: 10.1002/jhbp. 810.
  • Homayounfar K, Bleckmann A, Conradi LC, Sprenger T, Lorf T, Niessner M et al. Metastatic recurrence after complete resection of colorectal liver metastases: impact of surgery and chemotherapy on survival. Int J Colorectal Dis. 2013 Jul;28 (7):1009-17. doi: 10.1007/s00384-013-1648-2. Epub 2013 Feb 1. PMID: 23371333; PMCID: PMC3712136.
  • Liu W, Sun Y, Zhang L, Xing BC. Negative surgical margin improved long-term survival of colorectal cancer liver metastases after hepatic resection: a systematic review and meta-analysis. Int J Colorectal Dis. 2015 0ct;30 (10):1365-73. doi: 10.1007/s00384-015-2323-6. Epub 2015 Jul 23. PMID: 26198997.
  • de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg. 2008 Oct;248 (4):626-37. doi: 10.1097/SLA. 0b013e31818a07f1. PMID: 18936576.
  • Sadot E, Groot Koerkamp B, Leal JN, Shia J, Gonen M, Allen PJ, DeMatteo RP, Kingham TP, Kemeny N, Blumgart LH, Jarnagin WR, D'Angelica MI. Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate? Ann Surg. 2015 Sep;262 (3):476-85; discussion 483-5. doi: 10.1097/SLA. 0000000000001427. PMID: 26258316; PMCID: PMC4533113.
  • Vigano L, Procopio F, Cimino MM, Donadon M, Gatti A, Costa G, Del Fabbro D, Torzilli G. Is Tumor Detachment from Vascular Structures Equivalent to R0 Resection in Surgery for Colorectal Liver Metastases? An Observational Cohort. Ann Surg Oncol. 2016 Apr;23 (4):1352-60. doi: 10.1245/s10434-015-5009-y. Epub 2015 Dec 29. PMID: 26714946.
  • Andreou A, Knitter S, Schmelzle M, Kradolfer D, Maurer MH, Auer TA, Fehrenbach U, Lachenmayer A, Banz V, Schöning W, Candinas D, Pratschke J, Beldi G. Recurrence at surgical margin following hepatectomy for colorectal liver metastases is not associated with R1 resection and does not impact survival. Surgery. 2021 May;169 (5):1061-1068. doi: 10.1016/j. surg. 2020.11.024. Epub 2020 Dec 30. PMID: 33386128.]
  • Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020 Sep 1;38 (25):2830-2838. doi: 10.1200/JCO. 20.00818. Epub 2020 Jun 2. PMID: 32484754; PMCID: PMC7460150.
  • Sawrie SM, Fiveash JB, Caudell JJ. Stereotactic body radiation therapy for liver metastases and primary hepatocellular carcinoma: normal tissue tolerances and toxicity. Cancer Control. 2010 Apr;17 (2):111-9. doi: 10.1177/107327481001700206. PMID: 20404794.
  • Kennedy AS. Radiation oncology approaches in liver malignancies. Am Soc Clin Oncol Educ Book. 2014: e150-5. doi: 10.14694/EdBook_AM. 2014.34. e150. PMID: 24857096.
  • Méndez Romero A, de Man RA. Stereotactic body radiation therapy for primary and metastatic liver tumors: From technological evolution to improved patient care. Best Pract Res Clin Gastroenterol. 2016 Aug;30 (4):603-16. doi: 10.1016/j. bpg. 2016.06.003. Epub 2016 Jun 25. PMID: 27644908.
  • van der Pool AE, Mendez RA, Wunderink W, et al. Stereotactic body radiation therapy for colorectal liver metastases. Br. J. Surg. 97 [3], 377-382. 2010.
  • Scorsetti M, Comito T, Tozzi A, Navarria P, Fogliata A, Clerici E, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2015;141 (3):543-53. doi: 10.1007/s00432-014-1833-x. PMID: 25245052.
  • Ahmed KA, Caudell JJ, El-Haddad G, Berglund AE, Welsh EA, Yue B et al. Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016;95 (5):1399-1404. doi: 10.1016/j. ijrobp. 2016.03.050. PMID: 27319288; PMCID: PMC7771381.
  • Doi H, Uemoto K, Suzuki O, Yamada K, Masai N, Tatsumi D, et al. Effect of primary tumor location and tumor size on the response to radiotherapy for liver metastases from colorectal cancer. Oncol Lett. 2017 Jul;14 (1):453-460. doi: 10.3892/ol. 2017.6167. Epub 2017 May 12. PMID: 28693191; PMCID: PMC5494798.
  • Joo JH, Park JH, Kim JC, Yu CS, Lim SB, Park IJ, et al. Local Control Outcomes Using Stereotactic Body Radiation Therapy for Liver Metastases From Colorectal Cancer. Int J Radiat Oncol Biol Phys. 2017 Nov 15;99 (4):876-883. doi: 10.1016/j. ijrobp. 2017.07.030. Epub 2017 Jul 31. PMID: 29063852.
  • Vernaleone M, Bonomo P, Di Cataldo V, Saieva C, Masi L, Desideri I et al. Robotic stereotactic radiotherapy for liver oligometastases from colorectal cancer: a single-center experience. Radiol Med. 2019 Sep;124 (9):870-876. doi: 10.1007/ s11547-019-01042-8. Epub 2019 May 18. PMID: 31104277.
  • Эффективность стереотаксической лучевой терапии у больных с метастатическим поражением печени / С. И. Ткачев, Ю. И. Патютко, С. В. Медведев [и др.] // Анналы хирургической гепатологии. - 2016. - Т. 21. -№1. - С. 38-43.
  • Введение термина «ключевой узел» в области комбинированного лечения больных колоректальным раком с метастазами в печени / И. В. Сагайдак, А. В. Назаренко, С. И. Ткачев [и др.] // Сборник научных работ III Петербургского Международного онкологического форума «Белые ночи 2017», Санкт-Петербург, 22-24 июня 2017 года / ФГБУ «НИИ онкологии им. Н. Н. Петрова» Минздрава России. - Санкт-Петербург: АННМО «Вопросы онкологии», 2017. - С. 92.
  • Hao W., Binbin J., Wei Y,. Kun Y. Can Radiofrequency Ablation Replace Liver Resection for Solitary Colorectal Liver Metastasis? A Systemic Review and Meta-Analysis. Front. Oncol. 2020 2020 Nov 17;10:561669. doi: 10.3389/fonc. 2020.561669.
  • Meijerink MR, Puijk RS, van Tilborg AAJM, Henningsen KH, Fernandez LG, Neyt M, Heymans J et al. Radiofrequency and Microwave Ablation Compared to Systemic Chemotherapy and to Partial Hepatectomy in the Treatment of Colorectal Liver Metastases: A Systematic Review and Meta-Analysis. Cardiovasc Intervent Radiol. 2018;41 (8):1189-1204. doi: 10.1007/s00270-018-1959-3. PMID: 29666906; PMCID: PMC6021475.
  • Puijk RS, Ruarus AH, Vroomen LGPH et al. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial BMC Cancer 2018 Aug 15;18 (1):821. doi: 10.1186/s12885-018-4716-8.
  • Shady W, Petre EN, Do KG, Gonen M, Yarmohammadi H, Brown KT, et al. Percutaneous Microwave versus Radiofrequency Ablation of Colorectal Liver Metastases: Ablation with Clear Margins (A0) Provides the Best Local Tumor Control. J Vasc Interv Radiol. 2018 Feb;29 (2):268-275. e1. doi: 10.1016/j. jvir. 2017.08.021. Epub 2017 Dec 6. PMID: 29203394; PMCID: PMC5803367.
  • Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg. 2007 Oct;246 (4):559-65; discussion 565-7. doi: 10.1097/SLA. 0b013e318155a7b6. PMID: 17893492.
  • Kennedy TJ, Cassera MA, Khajanchee YS, Diwan TS, Hammill CW, Hansen PD. Laparoscopic radiofrequency ablation for the management of colorectal liver metastases: 10-year experience. J Surg Oncol. 2013 Mar;107 (4):324-8. doi: 10.1002/jso. 23268. Epub 2012 Sep 20. PMID: 22996143.]
  • Leung U, Kuk D, D'Angelica MI, Kingham TP, Allen PJ, DeMatteo RP, et al. Long-term outcomes following microwave ablation for liver malignancies. Br J Surg. 2015 Jan;102 (1):85-91. doi: 10.1002/bjs. 9649. Epub 2014 Oct 9. PMID: 25296639; PMCID: PMC4593505.
  • Shady W, Petre EN, Gonen M, Erinjeri JP, Brown KT, Covey AM, et al. Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes—A 10-year Experience at a Single Center. Radiology. 2016 Feb;278 (2):601-11. doi: 10.1148/radiol. 2015142489. Epub 2015 Aug 12. PMID: 26267832; PMCID: PMC4734163.
  • Cannon R, Ellis S, Hayes D, Narayanan G, Martin RC 2nd. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol. 2013 Apr;107 (5):544-9. doi: 10.1002/jso. 23280. Epub 2012 Oct 22. PMID: 23090720.
  • Hosein PJ, Echenique A, Loaiza-Bonilla A, Froud T, Barbery K, Rocha Lima CM, Yrizarry JM, Narayanan G. Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system. J Vasc Interv Radiol. 2014;25 (8):1233-1239. e2. doi: 10.1016/j. jvir. 2014.04.007.
  • Niessen C, Beyer LP, Pregler B, Dollinger M, Trabold B, Schlitt HJ, J et al. Percutaneous Ablation of Hepatic Tumors Using Irreversible Electroporation: A Prospective Safety and Midterm Efficacy Study in 34 Patients. J Vasc Interv Radiol. 2016;27 (4):480-6. doi: 10.1016/j. jvir. 2015.12.025.
  • Lee J, Shin IS, Yoon WS, Koom WS, Rim CH. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review. Radiother Oncol. 2020 Apr;145:63-70. doi: 10.1016/j. radonc. 2019.12.004.
  • Wang C, Wang H, Yang W, Hu K, Xie H, Hu KQ, et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology. 2015 May;61 (5):1579-90. doi: 10.1002/ hep. 27548. Epub 2015 Mar 20. PMID: 25284802.]
  • Littrup PJ, Aoun HD, Adam B, Krycia M, Prus M, Shields A. Percutaneous cryoablation of hepatic tumors: long-term experience of a large U. S. series. Abdom Radiol (NY). 2016 Apr;41 (4):767-80. doi: 10.1007/s00261-016-0687-x.
  • Glazer DI, Tatli S, Shyn PB, Vangel MG, Tuncali K, Silverman SG. Percutaneous Image-Guided Cryoablation of Hepatic Tumors: Single-Center Experience With Intermediate to Long-Term Outcomes. AJR Am J Roentgenol. 2017;209 (6):1381-1389. doi:10.2214/AJR. 16.17582
  • Di Martino M, Rompianesi G, Mora-Guzmán I, Martín-Pérez E, Montalti R, Troisi RI. Systematic review and me-ta-analysis of local ablative therapies for resectable colorectal liver metastases. Eur J Surg Oncol. 2020 May;46 (5):772-781. doi: 10.1016/j. ejso. 2019.12.003. Epub 2019 Dec 4. PMID: 31862133.
  • Aliberti C, Tilli M, Benea G, Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res. 2006 Sep-Oct;26 (5B): 3793-5. PMID: 17094403.
  • Richardson AJ, Laurence JM, Lam VW. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. J Vasc Interv Radiol. 2013 Aug;24 (8):1209-17. doi: 10.1016/j. jvir. 2013.05.055. PMID: 23885916
  • Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, Mambrini A, Montagnani F, Alessandroni P, Catalano V, Coschiera P. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012 Apr;32 (4):1387-95. Erratum in: Anticancer Res. 2013 Nov;33 (11):5211. PMID: 22493375.
  • Martin RC 2nd, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, Kelly LR, Garcia-Monaco RD, Sharma VR, Crocenzi TS, Strasberg SM. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015 Oct 15;121 (20):3649-58. doi: 10.1002/cncr. 29534. Epub 2015 Jul 6. PMID: 26149602.
  • Akinwande O, Dendy M, Ludwig JM, Kim HS. Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: A systematic review. Surg Oncol. 2017 Sep;26 (3):268-275. doi: 10.1016/j. suronc. 2017.05.003. Epub 2017 May 22. PMID: 28807246.
  • Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, Dutton P, Love S, Gebski V, Gray A; FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators, van Hazel G, Sharma RA. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017 Sep;18 (9):1159-1171. doi: 10.1016/S1470-2045 (17) 30457-6. Epub 2017 Aug 3. PMID: 28781171; PMCID: PMC5593813.
Еще
Статья научная
SciUp 2024 © 2024 ©